» Articles » PMID: 35628611

Development and Characterization of a Factor V-Deficient CRISPR Cell Model for the Correction of Mutations

Overview
Journal Int J Mol Sci
Publisher MDPI
Date 2022 May 28
PMID 35628611
Authors
Affiliations
Soon will be listed here.
Abstract

Factor V deficiency, an ultra-rare congenital coagulopathy, is characterized by bleeding episodes that may be more or less intense as a function of the levels of coagulation factor activity present in plasma. Fresh-frozen plasma, often used to treat patients with factor V deficiency, is a scarcely effective palliative therapy with no specificity to the disease. CRISPR/Cas9-mediated gene editing, following precise deletion by non-homologous end-joining, has proven to be highly effective for modeling on a HepG2 cell line a mutation similar to the one detected in the factor V-deficient patient analyzed in this study, thus simulating the pathological phenotype. Additional CRISPR/Cas9-driven non-homologous end-joining precision deletion steps allowed correction of 41% of the factor V gene mutated cells, giving rise to a newly developed functional protein. Taking into account the plasma concentrations corresponding to the different levels of severity of factor V deficiency, it may be argued that the correction achieved in this study could, in ideal conditions, be sufficient to turn a severe phenotype into a mild or asymptomatic one.

Citing Articles

CRISPR/Cas9-Mediated Generation of -Deficient Keratinocyte Model of Recessive Dystrophic Epidermolysis Bullosa.

Alipour F, Ahmadraji M, Yektadoost E, Mohammadi P, Baharvand H, Basiri M Cell J. 2023; 25(10):665-673.

PMID: 37865875 PMC: 10591263. DOI: 10.22074/cellj.2023.1989321.1225.

References
1.
Weyand A, Grzegorski S, Rost M, Lavik K, Ferguson A, Menegatti M . Analysis of factor V in zebrafish demonstrates minimal levels needed for early hemostasis. Blood Adv. 2019; 3(11):1670-1680. PMC: 6560344. DOI: 10.1182/bloodadvances.2018029066. View

2.
Tabibian S, Shiravand Y, Shams M, Safa M, Gholami M, Heydari F . A Comprehensive Overview of Coagulation Factor V and Congenital Factor V Deficiency. Semin Thromb Hemost. 2019; 45(5):523-543. DOI: 10.1055/s-0039-1687906. View

3.
Peyvandi F, Di Michele D, Bolton-Maggs P, Lee C, Tripodi A, Srivastava A . Classification of rare bleeding disorders (RBDs) based on the association between coagulant factor activity and clinical bleeding severity. J Thromb Haemost. 2012; 10(9):1938-43. DOI: 10.1111/j.1538-7836.2012.04844.x. View

4.
Canver M, Bauer D, Dass A, Yien Y, Chung J, Masuda T . Characterization of genomic deletion efficiency mediated by clustered regularly interspaced short palindromic repeats (CRISPR)/Cas9 nuclease system in mammalian cells. J Biol Chem. 2014; 289(31):21312-24. PMC: 4118095. DOI: 10.1074/jbc.M114.564625. View

5.
Shulman M, Nahmias Y . Long-term culture and coculture of primary rat and human hepatocytes. Methods Mol Biol. 2012; 945:287-302. PMC: 3781339. DOI: 10.1007/978-1-62703-125-7_17. View